These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
296 related articles for article (PubMed ID: 22313595)
21. Systematic comparison of plasma EBV DNA, anti-EBV antibodies and miRNA levels for early detection and prognosis of nasopharyngeal carcinoma. Tan LP; Tan GW; Sivanesan VM; Goh SL; Ng XJ; Lim CS; Kim WR; Mohidin TBBM; Mohd Dali NS; Ong SH; Wong CY; Sawali H; Yap YY; Hassan F; Pua KC; Koay CE; Ng CC; Khoo AS; Int J Cancer; 2020 Apr; 146(8):2336-2347. PubMed ID: 31469434 [TBL] [Abstract][Full Text] [Related]
22. Comparison of Epstein-Barr Virus Serological Tools for the Screening and Risk Assessment of Nasopharyngeal Carcinoma: a Large Population-based Study. Guo J; Cui Z; Zheng Y; Li X; Chen Y Pathol Oncol Res; 2020 Oct; 26(4):2185-2190. PubMed ID: 32222897 [TBL] [Abstract][Full Text] [Related]
23. Epstein-Barr virus mRNA profiles and viral DNA methylation status in nasopharyngeal brushings from nasopharyngeal carcinoma patients reflect tumor origin. Ramayanti O; Juwana H; Verkuijlen SA; Adham M; Pegtel MD; Greijer AE; Middeldorp JM Int J Cancer; 2017 Jan; 140(1):149-162. PubMed ID: 27600027 [TBL] [Abstract][Full Text] [Related]
24. Modulation of the tumor microenvironment by Epstein-Barr virus latent membrane protein 1 in nasopharyngeal carcinoma. Yoshizaki T; Kondo S; Endo K; Nakanishi Y; Aga M; Kobayashi E; Hirai N; Sugimoto H; Hatano M; Ueno T; Ishikawa K; Wakisaka N Cancer Sci; 2018 Feb; 109(2):272-278. PubMed ID: 29247573 [TBL] [Abstract][Full Text] [Related]
25. Circulation EBV Mir-Bart-7 Relating to Clinical Manifestation in Nasopharyngeal Carcinoma. Wardana T; Gunawan L; Herawati C; Oktriani R; Anwar S; Astuti I; Aryandono T; Mubarika S Asian Pac J Cancer Prev; 2020 Sep; 21(9):2777-2782. PubMed ID: 32986380 [TBL] [Abstract][Full Text] [Related]
26. Association between EBNA2 and LMP1 subtypes of Epstein-Barr virus and nasopharyngeal carcinoma in Thais. Tiwawech D; Srivatanakul P; Karalak A; Ishida T J Clin Virol; 2008 May; 42(1):1-6. PubMed ID: 18180201 [TBL] [Abstract][Full Text] [Related]
27. Molecular characterization of Epstein-Barr virus and oncoprotein expression in nasopharyngeal carcinoma in Korea. Jeon YK; Lee BY; Kim JE; Lee SS; Kim CW Head Neck; 2004 Jul; 26(7):573-83. PubMed ID: 15229899 [TBL] [Abstract][Full Text] [Related]
28. NF-κB Signaling Regulates Expression of Epstein-Barr Virus BART MicroRNAs and Long Noncoding RNAs in Nasopharyngeal Carcinoma. Verhoeven RJ; Tong S; Zhang G; Zong J; Chen Y; Jin DY; Chen MR; Pan J; Chen H J Virol; 2016 Jul; 90(14):6475-88. PubMed ID: 27147748 [TBL] [Abstract][Full Text] [Related]
29. The distinctive profile of risk factors of nasopharyngeal carcinoma in comparison with other head and neck cancer types. Abdulamir AS; Hafidh RR; Abdulmuhaimen N; Abubakar F; Abbas KA BMC Public Health; 2008 Dec; 8():400. PubMed ID: 19055849 [TBL] [Abstract][Full Text] [Related]
30. Evaluation of nasal and nasopharyngeal swab collection for the detection of Epstein-Barr virus in nasopharyngeal carcinoma. Coghill AE; Wang CP; Verkuijilen SAWM; Yu KJ; Hsu WL; Middeldorp JM; Hildesheim A J Med Virol; 2018 Jan; 90(1):191-195. PubMed ID: 28833336 [TBL] [Abstract][Full Text] [Related]
31. Epstein-Barr virus latent membrane protein 1 (EBV-LMP1) and tumor proliferation rate as predictive factors of nasopharyngeal cancer (NPC) radiation response. Gondhowiardjo S Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():323-31. PubMed ID: 10895175 [TBL] [Abstract][Full Text] [Related]
32. Head and neck cancer. An aetiopathogenetic study of non-endemic lymphoepithelioma. Casco FG; Ríos MJ; DE Miguel M; González T; Moreno Fernández AM; Galera-Ruiz H; González-Cámpora R; Drut R; Bacchi C; Galera-Davidson H Acta Otorhinolaryngol Ital; 2013 Feb; 33(1):9-15. PubMed ID: 23620634 [TBL] [Abstract][Full Text] [Related]
33. Various 30 and 69 bp deletion variants of the Epstein-Barr virus LMP1 may arise by homologous recombination in nasopharyngeal carcinoma of Tunisian patients. Hadhri-Guiga B; Khabir AM; Mokdad-Gargouri R; Ghorbel AM; Drira M; Daoud J; Frikha M; Jlidi R; Gargouri A Virus Res; 2006 Jan; 115(1):24-30. PubMed ID: 16154221 [TBL] [Abstract][Full Text] [Related]
34. Epstein-Barr virus detection in nasopharyngeal carcinoma: implications in a low-risk area. Breda E; Catarino RJ; Azevedo I; Lobão M; Monteiro E; Medeiros R Braz J Otorhinolaryngol; 2010; 76(3):310-5. PubMed ID: 20658009 [TBL] [Abstract][Full Text] [Related]
35. Prognostic value of serum Epstein-Barr virus antibodies in patients with nasopharyngeal carcinoma and undetectable pretreatment Epstein-Barr virus DNA. Yao JJ; Lin L; Jin YN; Wang SY; Zhang WJ; Zhang F; Zhou GQ; Cheng ZB; Qi ZY; Sun Y Cancer Sci; 2017 Aug; 108(8):1640-1647. PubMed ID: 28603915 [TBL] [Abstract][Full Text] [Related]
36. Epstein-Barr virus DNA load in nasopharyngeal brushings and whole blood in nasopharyngeal carcinoma patients before and after treatment. Adham M; Greijer AE; Verkuijlen SA; Juwana H; Fleig S; Rachmadi L; Malik O; Kurniawan AN; Roezin A; Gondhowiardjo S; Atmakusumah D; Stevens SJ; Hermani B; Tan IB; Middeldorp JM Clin Cancer Res; 2013 Apr; 19(8):2175-86. PubMed ID: 23493345 [TBL] [Abstract][Full Text] [Related]
37. Wild-type IDH2 contributes to Epstein-Barr virus-dependent metabolic alterations and tumorigenesis. Shi F; He Y; Li J; Tang M; Li Y; Xie L; Zhao L; Hu J; Luo X; Zhou M; Liu N; Fan J; Zhou J; Gao Q; Qiu S; Wu W; Zhang X; Jia W; Bode AM; Cao Y Mol Metab; 2020 Jun; 36():100966. PubMed ID: 32224436 [TBL] [Abstract][Full Text] [Related]
38. Negative plasma Epstein-Barr virus DNA nasopharyngeal carcinoma in an endemic region and its influence on liquid biopsy screening programmes. Nicholls JM; Lee VH; Chan SK; Tsang KC; Choi CW; Kwong DL; Lam KO; Chan SY; Tong CC; So TH; Leung TW; Luk MY; Khong PL; Lee AW Br J Cancer; 2019 Oct; 121(8):690-698. PubMed ID: 31527689 [TBL] [Abstract][Full Text] [Related]
39. Association of Epstein-Barr virus and nasopharyngeal carcinoma in Caucasian patients. Plaza G; Manzanal AI; Fogué L; Santón A; Martínez-Montero JC; Bellas C Ann Otol Rhinol Laryngol; 2002 Mar; 111(3 Pt 1):210-6. PubMed ID: 11913680 [TBL] [Abstract][Full Text] [Related]
40. EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy. Fang W; Zhang J; Hong S; Zhan J; Chen N; Qin T; Tang Y; Zhang Y; Kang S; Zhou T; Wu X; Liang W; Hu Z; Ma Y; Zhao Y; Tian Y; Yang Y; Xue C; Yan Y; Hou X; Huang P; Huang Y; Zhao H; Zhang L Oncotarget; 2014 Dec; 5(23):12189-202. PubMed ID: 25361008 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]